Leerink Partners Downgrades AbCellera Biologics (ABCL) to Market Perform
Tweet
Share
E-mail
Get Alerts ABCL Hot Sheet
Price: $12.70 +0.40%
Rating Summary:
11 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 5 | New: 19
Rating Summary:
11 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 7 | Down: 5 | New: 19
Join SI Premium – FREE
Leerink Partners analyst Faisal Khurshid downgraded AbCellera Biologics (NASDAQ: ABCL) from Outperform to Market Perform with a price target of $4.00.
For an analyst ratings summary and ratings history on AbCellera Biologics click here. For more ratings news on AbCellera Biologics click here.
Shares of AbCellera Biologics closed at $4.53 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- OpenAI: after the Hugging Face incident, we committed to conducting a much broader review of actions taken by our models
- Goldgroup Mining closes $122M private placement, exceeding initial target
- Pentagon-Backed Oil Company Is Set to Vie for Chevron's Crown in Venezuela - WSJ
Create E-mail Alert Related Categories
DowngradesRelated Entities
Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
